International Stem Cell Corporation announced that its oocyte collection and activation protocol has received the approval of an Institutional Review Board, a Federal requirement for all studies enrolling human subjects, and ensures appropriate subj

ISCO Chairman Kenneth Aldrich to speak on stem cell research at the Rodman & Renshaw 12th Annual Global Investment Conference on Healthcare on September 15, 2010 in New York City.

International Stem Cell Corporation announced that the United States Patent and Trademark Office has granted ISCO a patent relating to the company's development of human non-embryonic parthenogenetic stem cells. Human parthenogenetic stem cells are

International Stem Cell Corporation, an international pioneer and leader in stem cell research, announced that its wholly owned subsidiary, Lifeline Skin Care Inc., has achieved positive results in human safety tests of its cosmetic products and is m

International Stem Cell Corporation, an international pioneer and leader in stem cell research, begins its second pre-clinical phase of testing retinal pigment epithelium (RPE) derived from human parthenogenetic stem cells for the treatment of retina